A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity

Journal of Virology

Volumn 78, Issue 18, 2004, Pages 9842-9853

  Someya, Kenji ^a,b   Xin, Ke Qin ^b   Matsuo, Kazuhiro ^a   Okuda, Kenji ^b   Yamamoto, Naoki ^a   Honda, Mitsuo ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOKINE; GAMMA INTERFERON; PLASMID DNA; VACCINE; VACCINIA VACCINE; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNITY; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; STRUCTURAL GENE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; VACCINATION; VACCINIA VIRUS; VACCINIA VIRUS DI; VIRUS GENE; VIRUS RECOMBINANT; VIRUS RESISTANCE; VIRUS STRAIN;

AIDS VACCINES; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; GENES, GAG; GENES, POL; GENETIC VECTORS; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; RECOMBINATION, GENETIC; SAIDS VACCINES; SIMIAN IMMUNODEFICIENCY VIRUS; TH1 CELLS; VACCINES, DNA; VACCINIA VIRUS;

EID: 4444307111     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.18.9842-9853.2004     Document Type: Article

References (81)

1. Almond, N., K. Kent, M. Cranage, E. Rud, B. Clarke, and E. J. Stott. 1995. Protection by attenuated immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 345:1342-1344.
2. Amara, R. R., F. Villinger, J. D. Altman, S. L. Lydy, S. P. O'Neil, S. I. Staprans, D. C. Montefiori, Y. Xu, J. G. Herndon, L. S. Wyatt, M. A. Candido, N. L. Kozyr, P. L. Earl, J. M. Smith, H. L. Ma, B. D. Grimm, M. L. Hulsey, J. Miller, H. M. McClure, J. M. McNicholl, B. Moss, and H. L. Robinson. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292:69-74.
3. Asakura, Y., P. Lundholm, A. Kjerrstrom, R. Benthin, E. Lucht, J. Fukushima, S. Schwartz, K. Okuda, B. Wahren, and J. Hinkula. 1999. DNA-plasmids of HIV-1 induce systemic and mucosal immune responses. Biol. Chem. 380:375-379.
4. Baba, T. W., V. Liska, A. H. Khimani, N. B. Ray, P. J. Dailey, D. Penninck, R. Bronson, M. F. Greene, H. M. McCiure, L. N. Martin, and R. M. Ruprecht. 1999. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat. Med. 5:194-203.
5. Baig, J., D. B. Levy, P. F. McKay, J. E. Schmitz, S. Santra, R. A. Subbramanian, M. J. Kuroda, M. A. Lifton, D. A. Gorgone, L. S. Wyatt, B. Moss, Y. Huang, B. K. Chakrabarti, L. Xu, W. P. Kong, Z. Y. Yang, J. R. Mascola, G. J. Nabel, A. Carville, A. A. Lackner, R. S. Veazey, and N. L. Letvin. 2002. Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination. J. Virol. 76:11484-11490.
6. Bailer, R. T., A. Holloway, J. Sun, J. B. Margolick, M. Martin, J. Kostman, and L. J. Montaner. 1999. IL-13 and IFN-γ secretion by activated T cells in HIV-1 infection associated with viral suppression and lack of disease progression. J. Immunol. 162:7534-7542.
7. Barouch, D. H., A. Craiu, M. J. Kuroda, J. E. Schmitz, X. X. Zheng, S. Santra, J. D. Frost, G. R. Krivulka, M. A. Lifton, C. L. Crabbs, G. Heidecker, H. C. Perry, M. E. Davies, H. Xie, C. E. Nickerson, T. D. Steenbeke, C. I. Lord, D. C. Montefiori, T. B. Strom, J. W. Shiver, M. G. Lewis, and N. L. Letvin. 2000. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-12/Ig plasmid administration in rhesus monkeys. Proc. Natl. Acad. Sci. USA 97:4192-4197.
8. Belyakov, I. M., M. A. Derby, J. D. Ahlers, B. L. Kelsall, P. Earl, B. Moss, W. Strober, and J. A. Berzofsky. 1998. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc. Natl. Acad. Sci. USA 95:1709-1714.
9. Bernard, N. F., C. M. Yannakis, J. S. Lee, and C. M. Tsoukas. 1999. Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte activity in HIV-exposed seronegative persons. J. Infect. Dis. 179:538-547.
10. Billaut-Mulot, O., T. Idziorek, E. Ban, L. Kremer, L. Dupre, M. Loyens, G. Riveau, C. Locht, A. Capron, and G. M. Bahr. 2001. Interleukin-18 modulates immune responses induced by HIV-1 Nef DNA prime/protein boost vaccine. Vaccine 19:95-102.
11. Borrow, P. 1997. Mechanisms of viral clearance and persistence. J. Viral Hepatitis 4(Suppl. 2):16-24.
12. Boyer, J. D., B. Wang, K. E. Ugen, M. Agadjanyan, A. Javadian, P. Frost, K. Dang, R. A. Carrano, R. Ciecarelli, L. Coney, W. V. Williams, and D. B. Weiner. 1996. In vivo protective anti-HIV immune responses in non-human primate through DNA immunization. J. Med. Primatol. 25:242-250.
13. Boyer, J. D., K. E. Ugen, B. Wang, M. Agadjanyan, L. Gilbert, M. L. Bagarazzi, M. Chattergoon, P. Frost, A. Javadian, W. V. Williams, Y. Refaeli, R. B. Ciccarelli, D. McCallus, L. Coney, and D. B. Weiner. 1997. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat. Med. 3:526-532.
14. Chakrabarti, B. K., W. P. Kong, B. Y. Wu, Z. Y. Yang, J. Friborg, X. Ling, S. R. King, D. C. Montefiori, and G. J. Nabel. 2002. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J. Virol. 76:5357-5368.
15. Daniel, M. D., F. Kirchhoff, S. C. Czajak, P. K. Sehgal, and R. C. Desrosiers. 1992. Protective effects of a live attenuated SIV vaccine with a deletion in nef gene. Science 258:1880-1881.
16. Esparza, J., S. Osmanov, C. Pattou-Markovic, C. Toure, M. L. Chang, and S. Nixon. 2002. Past, present, and future of HIV vaccine trials in developing countries. Vaccine 20:1897-1898.
17. Ferrari, C., A. Penna, A. Bertoletti, A. Cavalli, G. Missale, V. Lamonaca, C. Boni, A. Valli, R. Bertoni, S. Urbani, P. Scognamiglio, and F. Fiaccadori. 1998. Antiviral cell-mediated immune responses during hepatitis B and hepatitis C virus infection. Rec. Results Cancer Res. 154:330-336.
18. + T-cell help in immunity to HIV. Vaccine 20:1961-1963.
19. Hel, Z., D. Venzon, M. Poudyal, W. P. Tsai, L. Giuliani, R. Woodward, C. Chougnet, G. Shearer, J. D. Altman, D. Watkins, N. Bischofberger, A. Abimiku, P. Markham, J. Tartaglia, and G. Franchini. 2000. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat. Med. 6:1140-1146.
20. Hiroi, T., H. Goto, K. Someya, M. Yanagita, M. Honda, N. Yamanaka, and H. Kiyono. 2001. HIV mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long-term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions. J. Immunol. 167:5862-5867.
21. Hofmann-Lehmann, R., J. Viasak, A. L. Williams, A. L. Chenine, H. M. McClure, D. C. Anderson, S. O'Neil, and R. M. Ruprecht. 2003. Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. AIDS 17:157-166.
22. Huang, Y., W. P. Kong, and G. J. Nabel. 2001. Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J. Virol. 75:4947-4951.
23. Hukkanen, V., E. Broberg, A. Salmi, and J. P. Eralinna. 2002. Cytokines in experimental herpes simplex virus infection. Int. Rev. Immunol. 21:355-371.
24. Igarashi, T., Y. Ami, H. Yamamoto, R. Shibata, T. Kuwata, R. Mukai, K. Shinohara, T. Komatsu, A. Adachi, and M. Hayami. 1997. Protection of monkeys vaccinated with vpr-and/or nef-defective simian immunodeficiency virus strain mac/human immunodeficiency virus type 1 chimeric viruses: a potential candidate live-attenuated human AIDS vaccine. J. Gen. Virol. 78(Pt. 5):985-989.
25. Ishii, K., Y. Ueda, K. Matsuo, Y. Matsuura, T. Kitamura, K. Kato, Y. Izumi, K. Someya, T. Ohsu, M. Honda, and T. Miyamura. 2002. Structural analysis of vaccinia virus DIs strain: application as a new replication-deficient viral vector. Virology 302:433-444.
26. Izumi, Y., Y. Ami, K. Matsuo, K. Someya, T. Sata, N. Yamamoto, and M. Honda. 2003. Intravenous inoculation of replication-deficient recombinant Vaccinia DIs expressing SIV Gag controls highly pathogenic SHIV in monkeys. J. Virol. 77:13248-13256.
27. Katz, A. 2003. HIV update. J. Obstet. Gynecol. Neonatal Nurs. 32:86.
28. Kaul, R., S. L. Rowland-Jones, J. Kimani, K. Fowke, T. Dong, P. Klama, J. Rutherford, E. Njagi, F. Mwangi, T. Rostron, J. Onyango, J. Oyugi, K. S. MacDonald, J. J. Bwayo, and F. A. Plummer. 2001. New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative sex workers. Immunol. Lett. 79:3-13.
29. Kent, S. J., A. Zhao, S. J. Best, J. D. Chandler, D. B. Boyle, and I. A. Ramshaw. 1998. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type-1 vaccine regimen consisting of consecutive priming with DNA and Boosting with recombinant fowlpox virus. J. Virol. 72:10180-10188.
30. Kitamura, T., Y. Kitamura, and I. Tagaya. 1967. Immunogenicity of an attenuated strain of vaccinia virus on rabbits and monkeys. Nature 215:1187-1188.
31. + HIV-specific T cells during progression to AIDS. Blood 99:2505-2511.
32. Kusakabe, K., K. Q. Xin, H. Katoh, K. Sumino, E. Hagiwara, S. Kawamoto, K. Okuda, Y. Miyagi, I. Aoki, K. Nishioka, D. Klinman, and K. Okuda. 2000. The timing of GM-CSF expression plasmid administration influence the Th1/Th2 response induced by an HIV-1 specific DNA vaccine. J. Immunol. 164:3102-3111.
33. Lu, S., J. Arthos, D. C. Montefiori, Y. Yasutomi, K. Manson, F. Mustafa, E. Johnson, J. C. Santoro, J. Wissink, J. I. Mullins, J. R. Haynes, N. L. Letvin, M. Wyand, and H. L. Robinson. 1996. Simian immunodeficiency virus DNA vaccine trial in macaques. J. Virol. 70:3978-3991.
34. Lusso, P. 2000. Chemokines and viruses: the dearest enemies. Virology 273:228-240.
35. Matsuo, K., Y. Nishino, T. Kimura, R. Yamaguchi, A. Yamazaki, T. Mikami, and K. Ikuta. 1992. Highly conserved epitope domain in major core protein p24 is structurally similar among human, simian, and feline immunodeficiency viruses. J. Gen. Virol. 73(Pt. 9):2445-2450.
36. McMichael, A. J., and S. L. Rowland-Jones. 2001. Cellular immune responses to HIV. Nature 410:980-987.
37. + T cell proliferation. Proc. Natl. Acad. Sci. USA 20:13878-13883.
38. Morita, M., Y. Aoyama, M. Arita, H. Amona, H. Yoshizawa, S. Hashizume, T. Komatsu, and I. Tagaya. 1977. Comparative studies of several vaccinia virus strains by intrathalamic inoculation into cynomolgus monkeys. Arch. Virol. 53:197-208.
39. Moss, R. B., E. Webb, W. K. Giermakowska, F. C. Jensen, J. R. Savary, M. R. Wallace, and D. J. Carlo. 2000. HIV-1-specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund adjuvant. J. Acquir. Immune. Defic. Syndr. 24:264-269.
40. Mothe, B. R., H. Horton, D. K. Carter, T. M. Allen, M. E. Liebl, P. Skinner, T. U. Vogel, S. Fuenger, K. Vielhuber, W. Rehrauer, N. Wilson, G. Franchini, J. D. Altman, A. Haase, L. J. Picker, D. B. Allison, and D. I. Watkins. 2002. Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection. J. Virol. 76:875-884.
41. Musey, L., J. Huges, T. Schacker, T. Shea, L. Corey, and M. J. McElrath. 1997. Cytotoxic-T-cell response and disease progression in early human immunodeficiency virus type 1 infection. N. Engl. J. Med. 337:1267-1274.
42. Mwau, M., and A. J. McMichael. 2003. A review of vaccines for HIV prevention. J. Gene Med. 5:3-10.
43. Nabel, G. J. 2002. HIV vaccine strategies. Vaccine 20:1945-1947.
44. Ogg, G. S., X. Jin, S. Bonhoeffer, P. R. Dunbar, M. A. Nowak, S. Monard, J. P. Segal, Y. Cao, S. L. Rowland-Jones, V. Cerundolo, A. Hurley, M. Markowitz, D. D. Ho, D. F. Nixon, and A. J. McMichael. 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma viral RNA. Science 279:2103-2106.
45. Ohga, S., A. Nomura, H. Takada, and T. Hara. 2002. Immunological aspects of Epstein-Barr virus infection. Crit. Rev. Oncol. Hematol. 44:203-215.
46. Okada, E., S. Sasaki, N. Ishii, I. Aoki, T. Yasuda, K. Nishioka, J. Fukushima, J. Miyazaki, B. Wahren, and K. Okuda. 1997. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 agents. J. Immunol. 159:3638-3647.
47. Okuda, K., A. Ihata, S. Watabe, E. Okada, T. Yamakawa, K. Hamajima, J. Yang, N. Ishii, M. Nakazawa, K. Ohnari, K. Nakajima, and K. Q. Xin. 2001. Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine 19:3681-3691.
48. Okuda, K., K. Q. Xin, A. Haruki, S. Kawamoto, Y. Kojima, F. Hirahara, H. Okada, D. Klinman, and K. Hamajima. 2001. Transplacental genetic immunization after intravenous delivery of plasmid DNA to pregnant mice. J. Immunol. 167:5478-5484.
49. + T cells in the mouse: application to vaccine research. Immunol. Lett. 85:215-222.
50. Pinto, L. A., J. Sullivan, J. A. Berzofsky, M. Clerici, H. A. Kessler, A. L. Landay, and G. M. Shearer. 1995. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative healthy care workers occupationally exposed to HIV-contaminated body fluid. J. Clin. Investig. 96:867-876.
51. Pisani, E., S. Lazzari, N. Walker, and B. Schwartlander. 2003. HIV surveillance: a global perspective. J. Acquir. Immune. Defic. Syndr. 32(Suppl. 1):S3-S11.
52. Pontesilli, O., M. R. Klein, S. R. Kerkhof-Garde, N. G. Pakker, F. de Wolf, H. Schuitemaker, and F. Miedema. 1998. Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response in associated with nonprogressive infection. J. Infect. Dis. 178:1008-1018.
53. Putkonen, P., M. Quesada-Rolander, A. C. Leandersson, S. Schwartz, R. Thorstensson, K. Okuda, B. Wahren, and J. Hinkula. 1998. Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts. Virology 250:293-301.
54. Qiu, J., R. Nayak, G. E. Tullis, and D. J. Pintel. 2002. Characterization of the transcription profile of adeno-associated virus type 5 reveals a number of unique features compared to previously characterized adeno-associated viruses. J. Virol. 76:12435-12447.
55. Rico, M. A., J. A. Quiroga, D. Subria, S. Castanon, J. M. Esteban, M. Pardo, and V. Carreno. 2001. Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha. Hepatology 33:295-300.
56. Rinaldo, C., X. L. Huang, Z. F. Fan, M. Ding, L. Beltz, A. Logar, D. Panicali, G. Mazzara, J. Liebmann, M. Cottrill, and P. Gupta. 1995. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J. Virol. 69:5838-5842.
57. Robinson, H. L., L. A. Hunt, and R. G. Webster. 1993. Protection against a lethal influenza virus challenge by immunization with a haemagglutine- expressing plasmid DNA. Vaccine 11:957-960.
58. + T cell responses associated with control of viremia. Science 278:1447-1450.
59. Rosenberg, E. S., L. LaRosa, T. Flynn, G. Robbins, and B. D. Walker. 1999. Characterization of HIV-1-specific T-helper cells in acute and chronic infection. Immunol. Lett. 66:89-93.
60. Rowland-Jones, S. L., D. F. Nixon, M. C. Aldhous, F. Gotch, K. Ariyoshi, N. Hallam, J. S. Kroll, K. Froebel, and A. McMichael. 1993. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 341:860-861.
61. Rowland-Jones, S. L., and A. McMichael. 1995. Immune responses in HIV-exposed seronegatives: have they repelled the virus? Curr. Opin. Immunol. 7:448-455.
62. Rowland-Jones, S., J. Sutton, K. Ariyoshi, T. Dong, F. Gotch, S. McAdam, D. Whitby, S. Sabally, A. Gallimore, T. Corrah, M. Takiguchi, T. Schultz, A. McMichael, and H. Whittle. 1995. HIV-specific cytotoxic T cells in HIV-exposed but uninfected Gambian women. Nat. Med. 1:59-64.
63. Sakaue, G., T. Hiroi, Y. Nakagawa, K. Someya, K. Iwatani, Y. Sawa, H. Takahashi, M. Honda, J. Kunisawa, and H. Kiyono. 2003. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses. J. Immunol. 170:495-502.
64. Sasaki, S., K. Sumino, K. Hamajima, J. Fukushima, N. Ishii, S. Kawamoto, H. Mohri, C. R. Kensil, and K. Okuda. 1998. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes. J. Virol. 72:4931-4939.
65. Shearer, G. M., M. Clerici, A. Sarin, J. A. Berzofsky, and P. A. Henkart. 1995. Cytokines in immune regulation/pathogenesis in HIV infection. Ciba Found. Symp. 195:142-147.
66. Shibata, R., C. Siemon, S. C. Czajak, R. C. Desrosiers, and M. Martin. 1997. Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus. J. Virol. 71:8141-8148.
67. Shinohara, K., K. Sakai, S. Ando, Y. Ami, N. Yoshino, E. Takahashi, K. Someya, Y. Suzaki, T. Nakasone, Y. Sasaki, M. Kaizu, Y. Lu, and M. Honda. 1999. A highly pathogenic simian/human immunodeficiency virus with genetic changes in cynomolgus monkey. J. Gen. Virol. 80:1231-1240.
68. Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans, Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, L. Huang, V. A. Harris, R. S. Long, X. Liang, L. Handt, W. A. Schleif, L. Zhu, D. C. Freed, N. V. Persaud, L. Guan, K. S. Punt, A. Tang, M. Chen, K. A. Wilson, K. B. Collins, G. J. Heidecker, V. R. Fernandez, H. C. Perry, J. G. Joyce, K. M. Grimm, J. C. Cook, P. M. Keller, D. S. Kresock, H. Mach, R. D. Troutman, L. A. Isopi, D. M. Williams, Z. Xu, K. E. Bohannon, D. B. Volkin, D. C. Montefiori, A. Miura, G. R. Krivulka, M. A. Lifton, M. J. Kuroda, J. E. Schmitz, N. L. Letvin, M. J. Caulfield, A. J. Bett, R. Youil, D. C. Kaslow, and E. A. Emini. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency virus immunity. Nature 415:331-335.
69. Stickl, H., V. Hochstein-Mintzel, and H. C. Huber. 1973. Primary vaccination against smallpox after preliminary vaccination with the attenuated vaccinia virus strain MVA and the use of a new "vaccination stamp." Munch. Med. Wochenschr. 115:1471-1473. (In German.)
70. Tagaya, I., H. Amano, T. Komatu, N. Uchida, and H. Kodama. 1974. Supplement to the pathogenicity of an attenuated vaccinia virus, strain DIs, in cynomolgus monkeys. Jpn. J. Med. Sci. Biol. 27:215-228.
71. Tagaya, I., T. Kitamura, and Y. Sano. 1961. A new mutant of dermovaccinia virus. Nature 192:381-382.
72. Takahashi, H., J. Cohen, A., Hosmalin, K. B. Cease, R. Houghten, J. L. Cornette, C. DeLis, B. Moss, R. N. Germain, and J. A. Berzofsky. 1988. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 85:3105-3109.
73. Tartaglia, J., M. E. Perkus, J. Taylor, E. K. Norton, J. C. Audonnet, W. I. Cox, S. W. Davis, J. van der Hoeven, B. Meignier, M. Riviere, B. Languet, and E. Paoletti. 1992. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188:217-232.
74. Voss, G., J. Li, K. Manson, M. Wyand, J. Sodroski, and N. L. Letvin. 1995. Human immunodeficiency virus type 1 envelope glycoprotein-specific cytotoxic T lymphocytes in simian-human immunodeficiency virus-infected rhesus monkeys. Virology 208:770-775.
75. Wang, B., K. E. Ugen, V. Srikantan, M. G. Agadjanyan, K. Dang, Y. Refaeli, A. I. Sato, J. Boyer, W. V. Williams, and D. B. Weiner. 1993. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 90:4156-4160.
76. Watabe, S., K. Q. Xin, A. Ihata, L. J. Liu, A. Honsho, I. Aoki, K. Hamajima, B. Wahren, and K. Okuda. 2001. Protection against influenza virus challenge by topical application of influenza DNA vaccine. Vaccine 19:4434-4444.
77. + T cells from Epstein-Barr virus (EBV) seropositive donors. Clin. Exp. Immunol. 126:101-110.
78. + T cell proliferative ability but not loss of human immunodeficiency virus type 1 specific equates with progression to disease. J. Infect. Dis. 182:792-798.
79. Wodarz, D., and V. A. A. Jansen. 2001. The role of T cell help for antiviral CTL responses. J. Theor. Biol. 211:419-432.
80. Yasutomi, Y., H. L. Robinson, S. Lu, F. Mustafa, C. Lekutis, J. Arthos, J. I. Mullins, G. Voss, K. Manson, M. Wyand, and N. L. Letvin. 1996. Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys. J. Virol. 70:678-681.
81. Yoshino, N., Y. Ami, K. Someya, S. Ando, K. Shinohara, F. Tashiro, Y. Lu, and M. Honda. 2000. Protective immune responses induced by a non-pathogenic simian/human immunodeficiency virus (SHIV) against a challenge of a pathogenic SHIV in monkeys. Microbiol. Immunol. 44:363-372.